Teva Pharmaceutical Industries (NYSE:TEVA) Releases FY 2025 Earnings Guidance

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) updated its FY 2025 earnings guidance on Saturday. The company provided EPS guidance of 2.450-2.650 for the period, compared to the consensus EPS estimate of 2.560. The company issued revenue guidance of $16.8 billion-$17.2 billion, compared to the consensus revenue estimate of $17.2 billion.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the stock. Barclays dropped their price objective on shares of Teva Pharmaceutical Industries from $28.00 to $26.00 and set an "overweight" rating for the company in a report on Thursday, January 30th. Bank of America lifted their price target on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the company a "buy" rating in a research report on Thursday, May 8th. JPMorgan Chase & Co. upgraded Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a research note on Monday, May 12th. StockNews.com upgraded Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research note on Wednesday, April 23rd. Finally, Piper Sandler raised their price objective on shares of Teva Pharmaceutical Industries from $23.00 to $30.00 and gave the company an "overweight" rating in a research report on Friday, January 17th. Eight investment analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Buy" and a consensus target price of $24.43.

Teva Pharmaceutical Industries Stock Up 0.5%

Shares of NYSE TEVA opened at $16.95 on Friday. The company has a quick ratio of 0.75, a current ratio of 0.98 and a debt-to-equity ratio of 2.97. The firm's fifty day moving average is $15.34 and its 200 day moving average is $17.43. The company has a market cap of $19.22 billion, a price-to-earnings ratio of -11.69, a PEG ratio of 1.44 and a beta of 0.62. Teva Pharmaceutical Industries has a 52 week low of $12.47 and a 52 week high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported $0.52 EPS for the quarter, beating analysts' consensus estimates of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 9.91% and a positive return on equity of 42.46%. The firm had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the previous year, the business posted $0.48 EPS. The company's quarterly revenue was up 1.9% on a year-over-year basis. On average, equities research analysts expect that Teva Pharmaceutical Industries will post 2.5 earnings per share for the current year.

Hedge Funds Weigh In On Teva Pharmaceutical Industries

An institutional investor recently raised its position in Teva Pharmaceutical Industries stock. AQR Capital Management LLC lifted its holdings in Teva Pharmaceutical Industries Limited (NYSE:TEVA - Free Report) by 24.6% during the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 23,955 shares of the company's stock after purchasing an additional 4,732 shares during the period. AQR Capital Management LLC's holdings in Teva Pharmaceutical Industries were worth $368,000 at the end of the most recent reporting period. 54.05% of the stock is owned by hedge funds and other institutional investors.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.